Preference will be given to candidates with strong expertise in text mining, RNA-seq analysis, machine learning, and handling large publicly available datasets.
From Morgridge Institute for Research - Fri, 07 May 2021 18:18:46 GMT - View all Madison, WI jobs

Notice NOT-DA-21-051 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-21-236 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated exploratory clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The trials must address questions within the mission and research interests of the NINDS and may evaluate drugs, biologics, and devices, as well as surgical, behavioral and rehabilitation therapies. Information about the mission and research interests of the NINDS can be found at the NINDS website (http://www.ninds.nih.gov/)

Notice NOT-DA-21-049 from the NIH Guide for Grants and Contracts

at least EUR 31,000 (the final salary will reflect qualifications and may be substantially higher): CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences: The Biomedical Sequencing Facility is Austria’s leading technology platform and service provider for next generation sequencing.... Vienna, Austria

Funding Opportunity RFA-DK-21-007 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for a Central Primary Reference Laboratory (CPRL) to provide support for the harmonization and standardization of laboratory measurements critical for clinical research in type 1 diabetes. The CPRL will provide administrative functions to coordinate harmonization efforts among clinical laboratories and commercial suppliers of reagents and methods, and will provide measurements of reference values for C-peptide and HbA1c measurements.

Notice NOT-HD-21-033 from the NIH Guide for Grants and Contracts

Notice NOT-MH-21-280 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-21-228 from the NIH Guide for Grants and Contracts. Reissue of PAR-17-485. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this National Institute of Mental Health (NIMH) R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs and advance the priorities outlined in the Office of AIDS Research (OAR) Annual Strategic Plan and the research program priorities of the NIMH Division of AIDS Research (DAR). To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Research Experiences and Mentoring Activities that either capitalize on existing networks of collaborating investigators or develop institute-based research education programs. Both research experiences and mentoring activities are required; research experiences are expected to be primary. Research Education Programs are expected to enhance the professional development of the participants and foster a career trajectory towards independent research in the mental health of HIV/AIDS.

Notice NOT-AG-21-024 from the NIH Guide for Grants and Contracts

Notice NOT-OD-21-120 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-NS-21-024 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue a small clinical trial to obtain critical information necessary to advance recording and/or stimulating devices to treat central nervous system disorders and better understand the human brain (e.g., Early Feasibility Study). Clinical studies supported may consist of acute or short-term procedures that are deemed Non-Significant Risk (NSR) by an Institutional Review Board (IRB), or Significant Risk (SR) studies that require an Investigational Device Exemption (IDE) from the FDA, such as chronic implants. The clinical trial should provide data to answer key questions about the function or final design of a device. This final device design may require most, if not all, of the non-clinical testing on the path to more advanced clinical trials and market approval. The clinical trial is expected to provide information that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. Activities supported by this Funding Opportunity include a small clinical trial to answer key questions about the function or final design of a device. As part of the BRAIN Initiative, NIH has initiated a Public-Private Partnership Program (BRAIN PPP) that includes agreements (Memoranda of Understanding, MOU) with a number of device manufacturers willing to make such devices available, including devices and capabilities not yet market approved but appropriate for clinical research. In general it is expected that the devices' existing safety and utility data will be sufficient to enable new IRB NSR or FDA IDE approval without need for significant additional non-clinical data. For more information on the BRAIN PPP, see http://braininitiative.nih.gov/BRAIN_PPP/index.htm

Funding Opportunity RFA-NS-21-023 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue translational activities and small clinical studies to advance the development of therapeutic, and diagnostic devices for disorders that affect the nervous or neuromuscular systems. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, obtaining an Investigational Device Exemption (IDE) for a Significant Risk (SR) study, as well as a subsequent small clinical study. The clinical study is expected to provide information about the device function or final design that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This FOA is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in negotiating the final project plan before award and monitoring of research progress.

Funding Opportunity RFA-AI-21-039 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to support consortia to conduct research toward the prevention and cure of HIV. The Consortium for Innovative HIV Vaccine and Cure Research will establish a collaborative and integrated research program built around two areas of scientific focus: identification of the correlates and the mechanism(s) of protection of preventive vaccine(s) and the use of vaccines or other immune modalities in advancing cure research. Preclinical studies in nonhuman primate (NHP) models will be supported to investigate the mechanism(s), by which efficacious AIDS vaccines protect NHPs from initial infection or establishment of systemic infection, and will incorporate vaccines or other immune interventions into cure strategies in SIV or SHIV-infected NHPs with the objective of eliminating virus reservoirs or establishing elite control of virus replication. Research findings can be applied to improve HIV vaccines and cure strategies and further advancement toward evaluation in human clinical trials.

Notice NOT-OD-21-118 from the NIH Guide for Grants and Contracts

Notice NOT-GM-21-049 from the NIH Guide for Grants and Contracts

Background in molecular biology, bioinformatics, genetics, or immunology is strongly preferred. A two-year postdoctoral fellowship (with the possibility of a…
From Medical College of Wisconsin - Thu, 06 May 2021 21:08:35 GMT - View all Milwaukee, WI jobs

Competitive Salary: F. Hoffmann-La Roche AG: The Early Biomarker Development Oncology (EBDO) Team is responsible for identification and validation of candidate molecular biomarkers used for demo Switzerland (CH)

£37,865-£45,359: Wellcome Sanger Institute: We are looking for a Senior Bioinformatician - Data Curator who will help us create a community data resource containing large collections of singl... Hinxton, Cambridgeshire

Notice NOT-CA-21-078 from the NIH Guide for Grants and Contracts